Compare Gilead Sciences, Inc. (GILD) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs ProShares UltraPro Short QQQ ETF — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while ProShares UltraPro Short QQQ ETF trades at $32.95 (market cap $2.23B). The key difference: Gilead Sciences, Inc. is far larger — about 81.8× ProShares UltraPro Short QQQ ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while ProShares UltraPro Short QQQ ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and ProShares UltraPro Short QQQ ETF for 12 Days on average.
| GILD | SQQQ | |
|---|---|---|
Market Cap | $182.40B | $2.23B |
Volume | 4,469,821 | 60,436,012 |
Sector | Health | Leveraged / Inverse |
52-Week High | $155.80 | $89.43 |
52-Week Low | $117.18 | $31.83 |
Typical Hold Time | 111 Days | 12 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 0.17% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings have mostly beaten expectations, though Q2 2026 saw a significant loss. The company maintains robust operating cash flow and has expanded access to its HIV prevention drug lenacapavir in Latin America, signaling growth potential in its core franchises.
The outlook is positive given analyst buy ratings and a $151.57 price target, but risks include negative net income margin and ROE in 2026, high debt levels, and reliance on pipeline success. The stock offers value if HIV and oncology advances materialize, yet investors face volatility from earnings inconsistencies and competitive pressures.
SQQQ (ProShares UltraPro Short QQQ) is trading at $33.37, up 4.02% today amid bearish technical signals. The ETF shows strong bearish momentum with moving averages indicating sell pressure while oscillators remain neutral. Recent news highlights SQQQ's role as a hedging tool against Nasdaq 100 declines, with financial media noting its strategic use during tech sector volatility.
The outlook remains tied to Nasdaq 100 performance, with SQQQ positioned to benefit from further tech weakness. Key risks include timing sensitivity and decay from daily rebalancing. Investment opportunity exists for tactical hedging but requires careful risk management due to the leveraged inverse structure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
